Show Summary Details
Page of

Chronic Obstructive Pulmonary Disease and Heart Disease 

Chronic Obstructive Pulmonary Disease and Heart Disease
Chronic Obstructive Pulmonary Disease and Heart Disease

Niharika Ganta

and Laura P. Gelfman

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 27 January 2020

Chronic obstructive pulmonary disease (COPD) and heart failure (HF) are chronic and life-limiting illnesses affecting millions of Americans. People living with these diseases have unique palliative care needs because they have a high symptom burden, unpredictable illness trajectories, and advanced therapies that may be available to them. This chapter outlines the distinct communication challenges that arise with these populations, offers communication strategies to use when educating these patients about their illness, and provides tools for eliciting their values and goals, especially after change in a patient’s health status. This chapter also discusses how to approach conversations regarding advanced therapies, including implantable cardioverter defibrillators, left ventricular assist devices, and mechanical ventilation. Finally, how to determine and discuss prognosis using validated tools such as Seattle Heart Failure Model and BODE Index are detailed.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.